|
|
|
|
| LEADER |
01587nmm a2200301 u 4500 |
| 001 |
EB000385007 |
| 003 |
EBX01000000000000000238059 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
130626 ||| eng |
| 020 |
|
|
|a 9783642148163
|
| 100 |
1 |
|
|a Rommel, Christian
|e [editor]
|
| 245 |
0 |
0 |
|a Phosphoinositide 3-kinase in Health and Disease
|h Elektronische Ressource
|b Volume 2
|c edited by Christian Rommel, Bart Vanhaesebroeck, Peter K. Vogt
|
| 250 |
|
|
|a 1st ed. 2011
|
| 260 |
|
|
|a Berlin, Heidelberg
|b Springer Berlin Heidelberg
|c 2011, 2011
|
| 300 |
|
|
|a X, 306 p. 79 illus., 46 illus. in color
|b online resource
|
| 653 |
|
|
|a Cancer
|
| 653 |
|
|
|a Cancer Biology
|
| 700 |
1 |
|
|a Vanhaesebroeck, Bart
|e [editor]
|
| 700 |
1 |
|
|a Vogt, Peter K.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a Current Topics in Microbiology and Immunology
|
| 028 |
5 |
0 |
|a 10.1007/978-3-642-14816-3
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-642-14816-3?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 616.994
|
| 082 |
0 |
|
|a 571.978
|
| 520 |
|
|
|a From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress. Here the authors give a brief overview of some key discoveries in the PI3K area and their impact, and include thoughts on the current state of the field, and where it could go from here
|